Carlo Zanotto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7287150/publications.pdf

Version: 2024-02-01

42	673	567281 15	610901 24
papers	citations	h-index	g-index

43	43	43	693
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine. Virology Journal, 2021, 18, 50.	3.4	1
2	Staphylococcus aureus RnpA Inhibitors: Computational-Guided Design, Synthesis and Initial Biological Evaluation. Antibiotics, 2021, 10, 438.	3.7	1
3	Computational Design and Development of Benzodioxane-Benzamides as Potent Inhibitors of FtsZ by Exploring the Hydrophobic Subpocket. Antibiotics, 2021, 10, 442.	3.7	10
4	Benzodioxaneâ€Benzamides as Antibacterial Agents: Computational and SAR Studies to Evaluate the Influence of the 7â€Substitution in FtsZ Interaction. ChemMedChem, 2020, 15, 195-209.	3.2	16
5	Benzamide Derivatives Targeting the Cell Division Protein FtsZ: Modifications of the Linker and the Benzodioxane Scaffold and Their Effects on Antimicrobial Activity. Antibiotics, 2020, 9, 160.	3.7	16
6	Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes. PLoS ONE, 2018, 13, e0190869.	2.5	1
7	2,6â€Difluorobenzamide Inhibitors of Bacterial Cell Division Protein FtsZ: Design, Synthesis, and Structureâ€“Activity Relationships. ChemMedChem, 2017, 12, 1303-1318.	3.2	23
8	Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4 ⁺ and CD8 ⁺ T-Cell Responses. Journal of Virology, 2017, 91, .	3.4	6
9	Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity. Antiviral Research, 2016, 134, 182-191.	4.1	3
10	Primeâ€“boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X. Virus Research, 2016, 225, 82-90.	2.2	1
11	Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: implications for HPV-tumor diagnosis and therapy. Journal of Translational Medicine, 2016, 14, 224.	4.4	12
12	Identification of antibiotic-resistant Escherichia coli isolated from a municipal wastewater treatment plant. Chemosphere, 2016, 164, 627-633.	8.2	34
13	3-(Benzodioxan-2-ylmethoxy)-2,6-difluorobenzamides bearing hydrophobic substituents at the 7-position of the benzodioxane nucleus potently inhibit methicillin-resistant Sa and Mtb cell division. European Journal of Medicinal Chemistry, 2016, 120, 227-243.	5.5	28
14	Removal of enteric viruses and Escherichia coli from municipal treated effluent by zebra mussels. Science of the Total Environment, 2016, 539, 395-400.	8.0	24
15	The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response. Antiviral Research, 2015, 116, 67-75.	4.1	4
16	A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. Journal of Translational Medicine, 2015, 13, 80.	4.4	19
17	Benzodioxaneâ€“benzamides as new bacterial cell division inhibitors. European Journal of Medicinal Chemistry, 2015, 89, 252-265.	5.5	45
18	L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines. Journal of Translational Medicine, 2013, 11, 95.	4.4	20

#	Article	IF	Citations
19	GFP co-expression reduces the A33R gene expression driven by a fowlpox vector in replication permissive and non-permissive cell lines. Journal of Virological Methods, 2013, 187, 172-176.	2.1	6
20	Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain. Virus Research, 2013, 178, 374-382.	2.2	6
21	A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers. Virus Research, 2012, 170, 44-52.	2.2	14
22	Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein. Journal of Translational Medicine, 2011, 9, 190.	4.4	12
23	Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis. Archives of Virology, 2010, 155, 915-924.	2.1	10
24	Canarypox and fowlpox viruses as recombinant vaccine vectors: A biological and immunological comparison. Antiviral Research, 2010, 88, 53-63.	4.1	23
25	Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. Journal of Translational Medicine, 2010, 8, 40.	4.4	9
26	MHC-restricted cytotoxic T-lymphocyte assay: An improved method based on normal and SV40-immortalized rabbit epidermal target cells. Journal of Virological Methods, 2009, 155, 77-81.	2.1	4
27	Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins. Journal of Virological Methods, 2009, 158, 184-189.	2.1	14
28	Telomerase Restrictors Might be A Novel Source for Screening Anti-HIV Agents. , 2007, , .		0
29	Prime-boost immunization with DNA, recombinant fowlpox virus and VLPSHIV elicit both neutralizing antibodies and IFNÎ³-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine, 2007, 25, 2128-2138.	3.8	22
30	Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses. Vaccine, 2005, 23, 4745-4753.	3.8	10
31	Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. Virology, 2003, 312, 181-195.	2.4	21
32	Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA/fowlpox priming and virus-like particle boosting. FEMS Immunology and Medical Microbiology, 2003, 35, 59-65.	2.7	7
33	Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV*1. Vaccine, 2003, 21, 2052-2064.	3.8	24
34	Evaluation of poliovirus vaccines for pestivirus contamination: non-specific amplification of poliovirus sequences by pan-pestivirus primers. Journal of Virological Methods, 2002, 102, 167-172.	2.1	3
35	Biological and conformational studies on analogues of a synthetic peptide enhancing HIV-1 infection. , 1998, 4, 436-448.		6
36	Minimal Sequence Requirements for Synthetic Peptides Derived from the V3 Loop of the Human Immunodeficiency Virus Type 1 (HIV-1) to Enhance HIV-1 Binding to Cells and Infection. Virology, 1995, 206, 807-816.	2.4	15

#	Article	IF	Citations
37	HIV-1 Infection of the Thymus: Evidence for a Cytopathic and Thymotropic Viral Variantin Vivo. AIDS Research and Human Retroviruses, 1995, 11, 11-19.	1.1	44
38	Pediatric HIV-1 Infection: Advances and Perspectives in Diagnosis and Prognosis. Antibiotics and Chemotherapy, 1994, 46, 5-17.	0.5	3
39	Mother-to-child HIV-1 transmission: Quantitative assessment of viral burden as a diagnostic tool and prognostic parameter in HIV-1-infected children. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 25-28.	1.5	4
40	Replication and tropism of human immunodeficiency virus type 1 as predictors of disease outcome in infants with vertically acquired infection. Journal of Pediatrics, 1993, 123, 929-936.	1.8	60
41	Pattern of Antibody Response against the V3 Loop in Children with Vertically Acquired		